{"id":496765,"date":"2020-07-17T13:58:02","date_gmt":"2020-07-17T13:58:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496765"},"modified":"2020-07-17T13:58:02","modified_gmt":"2020-07-17T13:58:02","slug":"peripheral-tcell-lymphomas-ptcl-emerging-and-marketed-drugs-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/peripheral-tcell-lymphomas-ptcl-emerging-and-marketed-drugs-2020_496765.html","title":{"rendered":"Peripheral T-Cell Lymphomas (PTCL) Emerging and Marketed Drugs, 2020"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Peripheral T-Cell Lymphomas (PTCL) Emerging and Marketed Drugs, 2020\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Peripheral T-Cell Lymphomas (PTCL) Emerging and Marketed Drugs, 2020\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Peripheral T-Cell Lymphomas (PTCL) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Peripheral T-Cell Lymphomas (PTCL) market. A detailed picture of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape is provided, which includes the disease overview and Peripheral T-Cell Lymphomas (PTCL) treatment guidelines. <\/div>\n<p style=\"text-align: justify;\">Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas that develop from mature T-cells and natural killer (NK) cells.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphomas-ptcl-pipeline-insight\" target=\"_blank\">Scope of Peripheral T-Cell Lymphoma&nbsp;Report<\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">The&nbsp;Peripheral T-Cell Lymphomas (PTCL)&nbsp;report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em>Peripheral T-Cell Lymphomas (PTCL)&nbsp;across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li class=\"ql-align-justify\">It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em>Peripheral T-Cell Lymphomas (PTCL)&nbsp;<em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li class=\"ql-align-justify\">Detailed&nbsp;Peripheral T-Cell Lymphomas (PTCL)&nbsp;<em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li class=\"ql-align-justify\"><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;Peripheral T-Cell Lymphomas (PTCL)&nbsp;.<\/li>\n<\/ul>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/peripheral-t-cell-lymphomas-ptcl-pipeline-insight\" target=\"_blank\">Request for sample pages<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">PTCL Emerging Drugs included in the report&nbsp;<\/p>\n<ol style=\"text-align: justify;\">\n<li>Denileukin diftitox: Eisai<\/li>\n<li>SP-02 (Darinaparsin, ZIO-101): Solasia Pharma<\/li>\n<li>Fenretinide (4-HPR): CerRx<\/li>\n<li>Tipifarnib: Kura Oncology<\/li>\n<li>HBI-8000: HUYA Bioscience International\/Quintiles, Inc.<\/li>\n<li>COPIKTRA (Duvelisib): Verastem<\/li>\n<li>Genolimzumab (GB226): Genor Biopharma<\/li>\n<li>Azacitidine (CC-486): Celgene Corporation<\/li>\n<li>Tislelizumab: BeiGene<\/li>\n<li>Lacutamab\/IPH4102: Innate Pharma<\/li>\n<li>AFM13: Affimed GmbH<\/li>\n<li>Opdivo (nivolumab) + Cabiralizumab: Bristol-Myers Squibb<\/li>\n<li>Bavencio (avelumab): Pfizer<\/li>\n<li>Keytruda (pembrolizumab): Merck Sharp &amp; Dohme Corp.<\/li>\n<li>STI-3031\/IMC-001: Sorrento Therapeutics<\/li>\n<li>ALRN 6924: Aileron Therapeutics<\/li>\n<li>Masitinib: AB Science<\/li>\n<li>Ruxolitinib: Incyte Corporation\/Novartis<\/li>\n<li>Aplidin (plitidepsin): PharmaMar<\/li>\n<li>ASTX660: Otsuka Pharmaceutical\/Astex Pharmaceuticals<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/peripheral-t-cell-lymphomas-ptcl-pipeline-insight\" target=\"_blank\">Table of contents<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Peripheral T-Cell Lymphomas (PTCL) &nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.1. Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.2. History&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.3. Peripheral T-Cell Lymphomas (PTCL) Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.4. Causes<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.5.Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6. Peripheral T-Cell Lymphomas (PTCL) Diagnosis&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6.1. Diagnostic Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Peripheral T-Cell Lymphomas (PTCL) &nbsp;Current Treatment Patterns<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1. Peripheral T-Cell Lymphomas (PTCL) Treatment Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Peripheral T-Cell Lymphomas (PTCL) &nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1. In-depth Commercial Assessment<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.1. Peripheral T-Cell Lymphomas (PTCL) &nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.1.1. Assessment Summary<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.2. Peripheral T-Cell Lymphomas (PTCL) &nbsp;Collaboration Deals<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.2.3. Peripheral T-Cell Lymphomas (PTCL) &nbsp;Acquisition Analysis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5. PTCL Therapeutic Assessment<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.1. Assessment by Phase of Development<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.2. Assessment by Product Type (Mono \/ Combination)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.2.1. Assessment by Stage and Product Type<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.3. Assessment by Route of Administration<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.3.1. Assessment by Stage and Route of Administration<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.4. Assessment by Molecule Type<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.4.1. Assessment by Stage and Molecule Type<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.5. Assessment by MOA<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.5.1. Assessment by Stage and MOA<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.6. Assessment by Target<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.6.1. Assessment by Stage and Target<\/span><\/p>\n<p style=\"text-align: justify;\"><span>6. Peripheral T-Cell Lymphomas (PTCL) Late Stage Products (Phase-III)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7. Peripheral T-Cell Lymphomas (PTCL) Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12. Peripheral T-Cell Lymphomas (PTCL) Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. Peripheral T-Cell Lymphomas (PTCL) &nbsp;Product Profiles<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1. Drug Name: Company&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.1.1. Product Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.1.2. Mechanism of action<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.2. Research and Development<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.2.1. Clinical Studies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3. Product Development Activities<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3.1. Collaboration<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3.2. Agreements<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3.3. Acquisition&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.3.4. Patent Detail<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.4. Tabulated Product Summary<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1.4.1. General Description Table<\/span><\/p>\n<p style=\"text-align: justify;\"><span>Detailed information in the report&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>14. Peripheral T-Cell Lymphomas (PTCL) &nbsp;Key Companies<\/span><\/p>\n<p style=\"text-align: justify;\"><span>15. Peripheral T-Cell Lymphomas (PTCL) &nbsp;Key Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16. Dormant and Discontinued Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1. Dormant Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1.1. Reasons for being dormant<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2. Discontinued Products&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2.1. Reasons for the discontinuation<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. Peripheral T-Cell Lymphomas (PTCL) &nbsp;Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18. Peripheral T-Cell Lymphomas (PTCL) &nbsp;Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. Peripheral T-Cell Lymphomas (PTCL) &nbsp;Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21. PTCL Report Methodology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>21.1. Secondary Research<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>21.2. Expert Panel Validation&nbsp;<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=peripheral-tcell-lymphomas-ptcl-emerging-and-marketed-drugs-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=peripheral-tcell-lymphomas-ptcl-emerging-and-marketed-drugs-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Peripheral T-Cell Lymphomas (PTCL) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Peripheral T-Cell Lymphomas (PTCL) market. A detailed picture of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/peripheral-tcell-lymphomas-ptcl-emerging-and-marketed-drugs-2020_496765.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-496765","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=496765"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496765\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=496765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=496765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=496765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}